Remove Animal Testing Remove Article Remove Drugs
article thumbnail

FDA Eliminates Animal Testing: Impact on Biotechs

The Premier Consulting Blog

On April 10, 2025, the US FDA announced that it has a long-term plan to eliminate conventional animal testing in drug development, starting with monoclonal antibodies (mAbs).[ One great example is the FDAs 505(b)(2) New Drug Application (NDA) pathway. 7] This was a landmark change in philosophy.

article thumbnail

The evolution of AI in drug discovery: learning from history’s mistakes (Part 2)

Drug Target Review

Sujeegar Jeevanandam, an expert with 13 years of experience in life sciences R&D, offers valuable insights into the current state and future trajectory of artificial intelligence in drug discovery. This breakthrough could fundamentally change how drugs are developed and tested.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

4 ways ex vivo models offer Pharma better alternatives to animal testing

Reprocell

Pharma companies are legally required to test novel drugs in animal models before beginning human trials. And while animal testing has progressed thousands of therapeutics that we use today, it is not without its experimental and ethical downfalls.

article thumbnail

Alternative testing methods covered by the FDA Modernization Act 2.0

Reprocell

A recent law passed in the USA means that new drugs do not need to be tested on animals before human studies. expands the range of models that can be used to test a compound before clinical trials. expands the range of models that can be used to test a compound before clinical trials.

FDA 52
article thumbnail

Analysis Life Sciences: FDA finalizes new guidance on nonclinical assessment of potential immunotoxicity

Agency IQ

FDA finalizes new guidance on nonclinical assessment of potential immunotoxicity Late last week the FDA released a final guidance document containing recommendations on the nonclinical assessment of potential immunotoxicity for drugs and certain biologics. What are nonclinical studies and when are they conducted in drug development?

FDA 52
article thumbnail

Article Periodic Thank You EPA issues new chemicals decision framework to assess eye irritation and corrosion

Agency IQ

The framework supports EPA’s mandate to develop and implement alternative test methods and strategies, or new approach methodologies (NAMs), that do not require vertebrate animal testing for assessing risk of injury to health or the environment. BY PATRICIA ISCARO, ESQ. |

article thumbnail

Article FDA Thank You FDA proposes first update to orthopedic device coating guidance since 1990s

Agency IQ

Further, other types of coatings or surface modifications are outside of the scope of the guidance – although, notably, the guidance may be able to provide some recommendations about coatings that contain a drug or biologic, but doesn’t “discuss drug or biologic characterization recommendations” – solely the coating material itself.

FDA 40